FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
The OncoAlert Newsletter is now out for June 23-29, 2023
Scientists say discovery may be linked to decades-long decline in sperm counts in men around the world
ABC comedy series White Fever highlights a type of racism that is nuanced and hard to detect, but is just as harmful to people of…
The BART trial aims to evaluate whether contemporary radiotherapy after standard-of-care surgery and chemotherapy reduces pelvic recurrences safely and also potentially affects survival in high-risk…
Objectives Development of evidence-based good practice recommendations for clinicians considering the use of antibiotics in patients towards the end of life. Design A multiprofessional group…
We call for a reevaluation of the long-standing dogmatic nutritional principle that âall foods fitâ for all cases of eating disorders (EDs) and its corollary,…
It may only make things worse.
Quality of post graduation medical education in India needs to reviewed to improve the quality of life of doctors and patient care.
Breast Cancer: New Horizons, Current Controversies is a comprehensive educational curriculum that encompasses the full range of breast cancer care. Topics include mechanisms of disease,…
Objectives: Prostate cancer accounted for more than 180,000 new cases and almost 40,000 deaths in the United States in 1998. Higher rates of mortality have…